Document:

Exhibit 10.7.1

 

AMENDMENT NO. 1 TO LICENSE AGREEMENT

 

This Amendment No. 1 to the License Agreement
(“Amendment”), having an effective , date of April 7, 2014 (“Amendment Effective Date”), is made and entered
by and between Ohio State Innovation Foundation, located at 1524 North High Street, Columbus, Ohio 43201 (“OSIF”) and
Microlin Bio, Inc., a New York based corporation located at 302A West 12th, New York, NY 10014 (“Licensee”).

 

BACKGROUND

 

OSIF and Licensee entered into a Patent
& Technology License Agreement dated September 6, 2013 (“License Agreement”) with respect to OSIF # A2014-0294;
and

 

OSIF and Licensee would like to amend and
modify the License Agreement as identified below and such amendment shall be incorporated as part of the License Agreement.

 

The parties agree as follows:

 

		1.	Definitions. All capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to
such terms in the License Agreement.

 

		2.	In Section 1, Patent Rights/Technology Rights shall be amended to include the information below:
	 	 	 

	
        App. No./

        Date of

        Filing

        [Tech ID#]
	 	Title	 	Inventor(s)	 	
        Jointly Owned?

        (Y/N; if Y, with

        whom?)
	 	Prosecution Counsel
	
        61/975,366

        April 4, 2014

        [2014-218]
	 	Lipid Nanoparticle Compositions and Methods of Making and Methods of Using the Same	 	R. Lee	 	x No	 	MacMillan, Sobanski, and Todd LLC

 

 

		3.	In Section 3.1(a), “Patent expenses due upon Effective Date” shall be amended to include the information below:
	 	 	 

	
        Patent expenses 

        due upon

        Effective Date
	 	Amount	 	
        based on invoices received 

        as of:

	Tech ID#2014-218	 	Current Estimate: $8,500 – invoice for 4/04/14 filing not yet received 	 	Reimbursement of past patent cost and future patent cost due upon Licensee receipt of invoice from OSIF

 

    	 1 of 3

    	 

    

 

		4.	Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original
and all of which together shall constitute an agreement, notwithstanding that all parties are not signatories to the same counterpart.

 

		5.	Continued Force and Effect. Except as provided in this Amendment, all terms, conditions, and provisions of the License
Agreement shall remain and continue in full force and effect as provided therein.

 

IN WITNESS WHEREOF, the parties hereto have
entered into this Amendment effective as of the Amendment Effective Date.

 

[AUTHORIZED SIGNATURES APPEAR ON THE FOLLOWING
PAGE]

 

    	 2 of 3

    	 

    

 

	OHIO STATE INNOVATION FOUNDATION	 	MICROLIN BIO, INC.
	 	 	 	 	 
	By:	/s/ Timothy R. Wright	 	By:	/s/ Joseph Hernandez
	 	 	 	 	 
	Name:	Timothy R. Wright	 	Name:	Joseph Hernandez
	 	 	 	 	 
	Title:	President	 	Title:	CEO & President
	 	 	 	 	 
	Date:	4-8-14	 	Date:	4-10-14

 

    	3 of 3Exhibit 10.16

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT
AGREEMENT (this “Agreement”), between Microlin Bio, Inc., a Delaware Corporation, with its principal place
of business at 302A West 12th Street, Suite 114, New York, NY 10014 (the “Company”) and Eric G. Marcusson, Ph.D.
of San Francisco (“Employee”), shall be effective as of the date that the Company’s registration statement on
Form S-1 is declared effective by the Securities and Exchange Commission (the “Effective Date”). Each of the Company
and Employee are hereafter sometimes referred to as a “Party” and collectively as the “Parties.”

 

1.          Preliminary
Premises.  In entering into this Agreement, the Parties acknowledge and agree as follows:

 

(a)          Employee
previously provided services to the Company as a consultant pursuant to a Consulting Agreement, dated November 22, 2013 (the “Consulting
Agreement”), which is hereby terminated, as of the Effective Date of this Agreement. Notwithstanding the foregoing, the Microlin
Bio Inc. Nonqualified Stock Option Agreement with a grant date of December 31, 2013, a copy of which is attached hereto as Exhibit
A (the “Option Agreement”), shall remain in full force and effect. In addition, the Company shall pay all monetary
obligations incurred by the Company and payable to Employee under the Consulting Agreement in accordance with the timing set forth
within the Consulting Agreement;

 

(b)          Employee
has the experience and skills desired by the Company for the position into which Employee is hired; and

 

(c)          The
Company wishes to hire Employee and Employee wishes to be employed by the Company under the terms and conditions set forth herein.

 

2.          Employment.
 The Company hereby employs Employee, and Employee hereby accepts such employment by the Company as of the Effective Date,
upon the terms and conditions set forth below.

 

3.          Term.
 The employment of Employee hereunder shall commence on the Effective Date and shall continue for a period of 2 years unless
it is terminated earlier in accordance with the provisions of Section 7. The period of Employee's employment with the Company is
hereafter referred to as the “Employment Period.” This term is subject to automatic renewal upon the mutual agreement
of the Parties for successive one-year terms, unless either Party gives written notice of its intent not to renew at least 60 days
prior to the expiration of the existing term, or where employment has been terminated pursuant to the provisions of Section 7 of
this Agreement.

 

4.          Duties.

 

(a)          Employee
shall serve as the Head of Preclinical Drug Discovery, with responsibility for the management of preclinical drug discovery operations
of the Company, together with such services and duties as the Company may direct as are consistent with his expertise and experience,
and subject to such terms and conditions as the Company shall determine. Employee shall report to, and serve under the general
supervision of the Chief Scientific Officer. Except at times when a physical presence is necessary at meetings, Employee may work
from a location other than the designated work place of Employee.

 

    	 

    	 

    

 

(b)          During
the Employment Period and after the achievement of the Financing Threshold referred to in Section 5, Employee shall devote Employee's
entire working time, attention and energies to the business of the Company. Employee shall perform the duties and responsibilities
of the position (i) with efficiency, diligence, care and conscientiousness, (ii) to the best of Employee's ability and to the reasonable
satisfaction of the Company, (iii) using at all times Employee's best efforts to promote and serve the interests of the Company,
and (iv) working with other employees of the Company in a competent and professional manner.

 

(c)          During
the Employment Period and after the achievement of the Financing Threshold referred to in Section 5, Employee shall not be engaged
in any other business activity, whether or not such activity is pursued for gain, profit or other pecuniary advantage. Notwithstanding
the foregoing, Employee shall not be prohibited from (i) owning up to one percent (1%) of the capital stock of any entity that
is publicly-traded on a U.S. national stock exchange or quotation system and does not manufacture, sell or distribute (at wholesale
or retail) Competitive Products (as hereafter defined), so long as such activities and/or ownership do not interfere with Employee's
duties and obligations hereunder. Employee shall not engage in any activities that conflict with, or create an appearance of conflict
with respect to, the interests of the Company.

 

5.           Compensation.

 

(a)          Employee’s
annual base salary shall be Two-Hundred and Twenty-Five Thousand Dollars ($225,000) (the “Base Salary”). Initially,
however, the Company shall pay in compensation for Employee's services hereunder, an annual salary of Fifty Thousand Dollars ($50,000)
(the “Initial Salary”), less withholdings, which shall be paid to Employee pursuant to the pay practices established
from time to the time by the Company (the “Initial Salary Period”). During the Initial Salary Period, the Company will
accrue the difference between the Base Salary and the Initial Salary paid to Employee on a daily basis (the “Accrued Amount”).
When and only if the Company raises at least $500,000 in the calendar year ended December 31, 2014, either through an initial public
offering of its common shares or from a private financing agreement that is reached and consummated to provide operational funds
for the Company until such time that the Company can raise funds in the public market (the “Financing Threshold”),
then the Accrued Amount shall be paid to Employee within fourteen days thereafter, provided that Employee remains employed by the
Company until the date that the Financing Threshold is satisfied. After the Company meets the Financing Threshold, Employee shall
be paid the Base Salary, subject to withholdings, along with any other compensation set forth herein. The Base Salary shall be
subject to an annual review by the Board of Directors of the Company.

 

(b)          Annual
performance based bonus up to 30% of Base Salary

 

(c)          During
the Employment Period, Employee also shall be entitled to the following benefits:

 

    	2

    	 

    

 

(i)          upon
fulfillment of the eligibility requirements under the applicable plan, such health benefits, group insurance, hospital, dental,
major medical and disability benefits and retirement benefits and other similar fringe benefits as are currently offered or hereafter
may be offered during the Employment Period to other employees of the Company at substantially the same employment level as Employee;
provided, however, that the Company may modify or discontinue any such benefit which it from time to time may maintain;

 

(ii)         Four
weeks of paid vacation during each calendar year, to be taken at times selected by Employee, with the approval of Chief Executive
Officer, as well as paid holidays and personal days according to the Company policy in effect from time to time; and

 

(iii)        reimbursement
for all reasonable and necessary expenses incurred in the ordinary course of Employee's employment hereunder, including travel
and entertainment expenses, except that each such expenditure shall be reimbursable only if it is of a nature qualifying it as
a proper deduction on the federal and state income tax returns of the Company, upon presentation by Employee of appropriate documentation,
sufficient for tax purposes to substantiate the expenditure an income tax deduction.

 

(d)          All
payments required to be made by the Company to Employee under this Agreement shall be subject to the withholding of such amounts
for taxes and other payroll deductions as the Company may reasonably determine it should withhold pursuant to any applicable law
or regulation. To the extent applicable, it is intended that the provisions of this Agreement comply with Internal Revenue Code
Section 409A (the “Code”) or be exempt therefrom, and this Agreement shall be administered, and all provisions of this
Agreement shall be construed, in a manner consistent with the requirements for avoiding taxes or penalties under Code Section 409A.
In the event that any payments or benefits hereunder are determined by the Company to be in the nature of nonqualified deferred
compensation payments, Employee and the Company hereby agree to use reasonable efforts to take such actions as may be mutually
agreed to ensure that such payments or benefits, to the extent possible, comply with the applicable provisions of Section 409A
of the Code and the official guidance issued thereunder. Notwithstanding the foregoing, the Company does not guarantee the tax
treatment or tax consequences associated with any payment or benefit arising under this Agreement. With regard to any provision
herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A of the Code:
(a) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (b) the
amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses
eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, and (c) such payments shall be made
on or before the last business day of Employee’s taxable year following the taxable year in which the expense occurred, or
such earlier date as required hereunder.

 

6.          Equity
Interest in Company. In addition to the Compensation set forth in Section 5 hereinabove, Employee is entitled to the stock
options provided in the Stock Option Agreement.

 

7.          Termination.
This Agreement may be terminated by the applicable Party and under the circumstances set forth below:

 

(a)          Death.
If Employee dies during the Employment Period, the employment of Employee hereunder shall be deemed to be terminated as of the
date of Employee's death.

 

    	3

    	 

    

 

(b)          Disability.
The Agreement shall terminate upon Employee’s disability. As used in this Agreement, the determination of “disability”
shall occur when Employee, due to a physical or mental disability, for a period of 90 consecutive days, or 180 days in the aggregate
whether or not consecutive, during any 360-day period, is unable to perform the services contemplated under this Agreement. Nothing
in this Section shall be construed to waive Employee’s rights, if any, under existing law, including, without limitation,
the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C.
§12101 et seq.

 

(c)          Resignation.
Employee may resign from employment, upon not less than thirty (30) days written notice,. Such resignation shall be with “Good
Reason” only if:

 

(i)          the
Company has materially breached this Agreement;

 

(ii)         there
has been a substantial reduction in the Employee’s responsibilities that are inconsistent with Employee’s status and
title; or

 

(iii)        the
Company requires Employee to perform or refrain from performing any act that would be in violation of applicable law.

 

(iv)        
the Company fails to reach the Financing Threshold referred to in Section 5 by June 1, 2014

 

However, with
the exception of the condition stated in Section 7(c)(iv) above, none of the foregoing events or conditions shall constitute Good
Reason unless: (x) the Employee provides the Company with written notice of such event or condition within 90 days of the occurrence
thereof, (y) the Company does not reverse or otherwise cure the event or condition within thirty (30) days of receiving the objection,
and (z) the Employee resigns from employment within thirty (30) days following the expiration of the cure period.

 

(d)          Termination
For Cause. The Company may terminate the employment of Employee hereunder at any time during the Employment Period for Cause
effective immediately upon written notice to Employee of such termination. Any such notice of termination shall provide sufficient
detail so as to enable Employee to determine the subsection of this provision relied upon by the Company in terminating this Agreement.
For purposes of this Agreement, “Cause” shall mean:

 

(i)          Employee's
gross incompetence or willful and serious misconduct, that is, or could reasonably be expected to be, injurious to the business,
operations or affairs of the Company;

 

(ii)         Employee's
breach of any of the provisions of Sections 9, 10, 11, 14 or 25 of this Agreement;

 

    	4

    	 

    

 

(iii)        Employee's
material breach of, or failure or refusal to perform, or habitual neglect of, any of the other duties and obligations of Employee
set forth in this Agreement (including but not limited to policies relating to discrimination or harassment), or such other material
duties as may be delegated to Employee commensurate with Employee's position, which is not cured within a period of thirty (30)
days following written notice thereof to Employee; provided that following the second such notice in any twelve (12) month period,
Employee shall not be entitled to any cure periods for any such further breaches, failures or refusals; and provided further, that
a breach of Sections 9, 10, 14 or 25 of this Agreement shall not be subject to any cure period;

 

(iv)        Employee's
commission of a felony in connection with the business, operations or affairs of the Company (including any business done with
any customers or suppliers) or a reasonable and substantiated determination by the Company that Employee is engaging in or has
engaged in fraud, misappropriation, dishonesty in financial dealings or embezzlement in connection with the business, operations
or affairs of the Company (including any business done with any customers or suppliers);

 

(v)         Employee's
conduct which is inconsistent with Employee's position and which results or is reasonably likely to result in a material adverse
effect (financial or otherwise) on the business or reputation of the Company, or which subjects, or if generally known would subject,
the Company to public ridicule or embarrassment;

 

(vi)        Employee's
alcohol or substance abuse that interferes with the performance by Employee of Employee's duties or obligations set forth in this
Agreement; or

 

(vii)       Expiration
of the Employment term as set forth in Section 3.

 

(e)          Separation
from Service. Notwithstanding anything set forth in Section 7 of this Agreement, a termination of employment shall be deemed
not to have occurred until such time as Employee incurs a “separation from service” with the Company in accordance
with Section 409a(a)(2)(A)(v) of the Code and the applicable provisions of Treasury Regulation Section 1.409A-3. Moreover, if Employee
is a “specified employee,” within the meaning of Section 409A of the Code (as determined pursuant to the Company’s
policy for identifying specified employees) on the date of Employee’s separation from service, then to the extent required
to comply with Section 409A of the Code, any severance payments under Section 8 hereof shall be paid or commence to be paid on
the first business day that is more than six months after the date of his separation from service.

 

8.          Effect
of Termination of Agreement.

 

(a)          Upon
termination of Employee's employment hereunder for Cause or if Employee resigns without Good Reason, Employee shall not have any
further rights or claims against the Company for compensation under Section 5 of this Agreement, except to receive:

 

(i)          the
unpaid portion of Employee's Base Salary provided for in Section 5(a) (or the Initial Salary if the Financing Threshold has not
yet been met), computed on a pro rata basis to the date of termination;

 

(ii)         payment
for all accrued but unused vacation days; and

 

(iii)        reimbursement
for expenses for which Employee has not yet been reimbursed.

 

    	5

    	 

    

 

(b)          Unless
Employee resigns without Good Reason or is terminated as a result of death or disability or for Cause by the Company, upon termination
of Employee’s employment hereunder, the Company shall pay the Employee an amount equal to six (6) months of Base Salary,
less applicable withholding amounts, in the form of a lump sum payment within sixty (60) days of termination, provided that Employee
executes a release and waiver of claims against the Company. To the extent required to comply with Section 409A of the Code, if
such sixty-day period begins in one calendar year and ends in the next calendar year, any lump sum payment provided under this
Section 8(b) shall be made in the later calendar year.

 

(c)          Upon
the termination of this Agreement for any reason, Employee shall have no right to any additional equity interest in the Company
in accordance with the provisions of Section 6, and the rights of Employee to any equity interest in the Company acquired
prior to the effective date of such termination shall be governed by the terms and conditions of the applicable incentive plan
and award agreement in effect at that time.

 

9.          Confidentiality
and Non-Disclosure.

 

(a)          Employee
recognizes that, as a valued employee of the Company, Employee occupies a position of trust with respect to business information
of a secret, proprietary or confidential nature that is the property of the Company and which has been or will be used by or imparted
to Employee from time to time in the course of the performance of Employee's duties hereunder. Employee acknowledges and agrees
that such Confidential Information (as hereafter defined) includes important, material and confidential trade secrets and proprietary
information of the Company, and materially affects the successful conduct of the Company's business, operations and goodwill. Employee
therefore agrees that:

 

(i)          Employee
shall not at any time during the Employment Period or thereafter, except in the good faith performance of Employee's duties hereunder,
use or disclose, directly or indirectly, for Employee's own behalf or to any third person or entity, any Confidential Information;
and

 

(ii)         Employee
shall return promptly on the termination of Employee's employment for whatever reason (or in the event of Employee's death, Employee's
personal representative shall return) to the Company at its direction and expense any and all copies of records, writings, computer
disks, materials, memoranda and other data pertaining to Confidential Information. Except in connection with the performance of
Employee's duties hereunder, Employee hereby agrees not to make or retain copies or excerpts or electronically transmit any Confidential
Information. The Company retains the right to examine any home or laptop computers or similar devices used by Employee and copy
and/or erase all Confidential Information contained on such computers or devices.

 

    	6

    	 

    

 

(b)          “Confidential
Information” means and includes (i) all knowledge, documents, data, information and material concerning the Company or its
business, products, operations, affairs, plans and financial condition and (ii) all information that has been disclosed to the
Company by any third party under an agreement or circumstances requiring such information to be kept confidential. Confidential
Information shall include, without limitation, the names, buying habits and procedures of Customers (as hereafter defined); marketing
methods and practices of the Company; pricing information relating to the Company, its products and its vendors and suppliers;
compensation paid to employees, terms of employment and other employee related matters; and financial information concerning the
Company. Confidential Information shall not include (w) information that is in the public domain through no fault of Employee,
(x) information published or disseminated by the Company in the ordinary course of business without restriction, (y) information
received from a third party not under an obligation to keep such information confidential and without breach of this Agreement
by Employee and (z) any knowledge as to potential customers, marketing methods, and business consulting technology, which
Employee can demonstrate was known or acquired by Employee before or after the Employment Period.

 

10.         Non-Competition;
Non-Solicitation.

 

(a)          Employee
hereby acknowledges and recognizes that Employee will be privy to Confidential Information constituting trade secrets, confidential
or proprietary information of the Company. Employee further acknowledges that Employee's position with the Company places Employee
in a special relationship and position of confidence and trust with the Customers, vendors, investors and employees of the Company.
In consideration of the promises contained herein and the consideration to be received by Employee pursuant to this Agreement,
the receipt and sufficiency of which are hereby acknowledged, Employee hereby agrees that during the Employment Period and the
six (6) month period following the effective date of termination of Employee's employment for Cause or as a result of Employee’s
Resignation without Good Reason (the “Restrictive Period”), Employee shall not, directly or indirectly, either on his
own behalf or on behalf of any other person or entity, whether as a principal, partner, member, officer director, employee, stockholder,
agent, joint venture, independent contractor or otherwise, in the United States:

 

(i)          engage
in the business of the development of diagnostic tests or microRNA-based therapeutic treatments for cancer (“Competitive
Products”);

 

(ii)         directly
or indirectly call on, solicit, communicate or consult with, write or respond to any Customer for the purpose of promoting, developing,
selling or distributing, at wholesale or retail, any Competitive Products, or otherwise attempt to induce any Customer to terminate,
modify or reduce such Customer's relationship with the Company; or

 

(iii)        employ,
hire, engage, solicit, recruit or otherwise induce or influence (including but not limited to, through the use of “headhunters,”
recruiters or employment agencies) any person who is or will be hereafter engaged (as an employee or agent,) by the Company to
terminate his or her employment or engagement.

 

(b)          As
used in this Section 10, “Customer” shall mean any person or entity to which the Company has done business within the
twelve (12) month period preceding the date of Employee's termination for Cause. If the Customer is part of a group of companies
which conduct business, through more than one entity, division or operating unit, whether or not separately incorporated or organized
(a “Customer Group”), the term “Customer” shall be deemed to include each such entity, division and operating
unit of the Customer Group, provided that Employee has actual knowledge of that such entity, division, or operating unit is part
of a Customer Group.

 

    	7

    	 

    

 

(c)          Employee
expressly declares that the provisions of this Section 10, including without limitation the territorial and time limitations contained
in this Section 10, are entirely reasonable at this time and are properly and necessarily required for the adequate protection
of the business, operations, trade secrets and goodwill of the Company. It is the desire and intent of the Parties that the provisions
of this Section 10 shall be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction
in which enforcement is sought. Accordingly, if any particular provisions of this Section 10, including without limitation any
territorial or time limitations, shall be adjudicated to be invalid or unenforceable, whether due to passage of time, change of
circumstances, or otherwise, the provisions of this Section 10 shall be deemed amended to delete therefrom the portion thus adjudicated
to be invalid or unenforceable, or to reduce said territorial or time limitations to such areas or periods of time as said court
shall deem reasonable, such deletion or reduction to apply only with respect to the operation of this Section 10 in the particular
jurisdiction in which such adjudication is made.

 

(d)          Employee
understands that the foregoing restrictions may limit to an extent Employee's ability to earn a livelihood in a business similar
to the business of the Company, but Employee nevertheless believes that Employee has received and will receive sufficient consideration
and other benefits pursuant to this Agreement to clearly justify such restrictions.

 

(e)          The
failure of the Company at any time to require performance by Employee of any provision hereunder shall in no way affect the right
of the Company thereafter to enforce the same; and the waiver by the Company of a breach of any provision of this Section 10
shall not operate as or be construed a waiver of any subsequent breach thereof.

 

11.         Inventions.
 The Company shall have all rights, including international priority rights, in all Inventions. As used herein, “Inventions”
shall mean all procedures, inventions, developments and discoveries, whether or not patentable, and all suggestions, proposals,
computer programs and writings, including any copyright interests therein, which Employee authors, conceives or makes, either solely
or jointly with others during Employee's employment with the Company which relate to any subject matter with which Employee's work
for Company may be concerned or involve the use of the time, equipment, materials or facilities of the Company. Employee shall
promptly disclose to the Company all Inventions and, at the Company's sole expense, give the Company all assistance it reasonably
requires to perfect, protect, and use its rights to Inventions. Employee hereby irrevocably appoint the Company as Employee's agent
and attorney-in-fact for purposes of effectuating the acts contemplated in this Section 11, such agency and power being an agency
and power coupled with an interest. The obligations of this Section 11 shall continue beyond the termination of Employee's employment
with the Company, whether the Inventions are patentable or not, if conceived or made by Employee during the Employment Period,
and shall be binding upon Employee's assigns, executors, administrators and other legal representatives.

 

    	8

    	 

    

 

12.         Extraordinary
Relief. Employee acknowledges and understands that the provisions of Sections 9, 10, 11 and 25 of this Agreement are of
a special and unique nature, the breach of which may cause the Company irreparable injury, and cannot adequately be compensated
for in damages by an action at law. In the event of a breach or threatened breach by Employee of any provision of such Sections,
the Company may seek an injunction restraining Employee from such actual or threatened breach. Nothing contained herein shall be
construed as prohibiting the Company from pursuing any other remedies (including, without limitation, an action for damages) available
for any actual or threatened breach of this Agreement, and the pursuit of any injunction or any other remedy shall not be deemed
an exclusive election of such remedy. The restrictions and limitations herein regarding non-competition, non-disclosure and non-solicitation
are in addition to, and not in derogation of, applicable law with respect to non-competition, non-disclosure and non-solicitation
in general.

 

13.         Assistance
in Litigation.  Employee shall, upon reasonable notice, furnish such information and proper assistance to the Company
as it may reasonably require, at the expense of the Company, in connection with any litigation in which it is, or may become, a
party either during or after the Employment Period. The Company shall compensate Employee for any time and expenses incurred by
Employee in connection therewith as mutually agreed by the Parties.

 

14.         No
Disparagement. Neither Party shall, during the Employment Period or at any time thereafter, except in connection with a
legal proceeding or order (including a proceeding relating to this Agreement) or as otherwise required by law, from and after the
date hereof, regardless of the expiration or termination of this Agreement, take
any action which is intended, or would reasonably be expected, to harm the the other Party or its or their reputation or which
would reasonably be expected to lead to unwanted or unfavorable publicity to the Company., or any of its managers, investors,
officers, agents or employees or, in the case of Employee, any of the Company's products.

 

15.         Indemnification.
To the extent permitted by applicable law, the Company shall defend, indemnify and save harmless the Employee from any liability
incurred by reason of any act or omission performed by the Employee while acting in good faith on behalf of the Company and within
the scope of authority of the Employee pursuant to this Agreement, except that the Employee must have in good faith believed that
the action was in, and not opposed to, the best interest of the Company, and with respect to any criminal action or proceeding,
had no reasonable cause to believe that the action was unlawful.

 

16.         Arbitration.

 

(a)          In
consideration of the Company employing Employee or continuing to employ Employee and the mutual promises set forth herein, Employee
and the Company agree, for themselves and for their representatives, successors, and assigns, that, subject to the proviso below,
any controversy or claim arising out of or relating to this Agreement, its enforcement or interpretation, or because of an alleged
breach, default, or misrepresentation in connection with any of its provisions, shall be settled by final and binding arbitration
in California (or such other place as may be agreed to by the Parties) before a single arbitrator, selected in accordance with
the Commercial Arbitration Rules of the American Arbitration Association ("AAA"), in accordance with the procedures required
under California law; provided, however, that in the event of a claimed violation of this Agreement, the Company may seek injunctive
relief in order to prevent irreparable harm or preserve the status quo.

 

(b)          To
the extent not inconsistent with law, the following will govern any arbitration hereunder (which shall take precedence over any
contrary rule of the AAA):

 

    	9

    	 

    

 

(i)          The
National Rules for the Resolution of Employment Disputes of the American Arbitration Association will apply. The arbitrator may
award any form of remedy or relief (including injunctive relief) that would otherwise be available in court, consistent with applicable
laws. Any award pursuant to said arbitration shall be accompanied by a written opinion of the arbitrator setting forth the reason
for the award, including findings of fact and conclusions of law. The award rendered by the arbitrator shall be conclusive and
binding upon the Parties hereto, and judgment upon the award may be entered, and enforcement may be sought in, any court of competent
jurisdiction or application may be made to such court for a judicial acceptance of the award and an order of enforcement.

 

(ii)         Except
as provided in this Agreement or as required by law, each Party shall pay its own expenses of arbitration and the expenses of the
arbitrator (including compensation) shall be borne equally by the Parties, except that if any matter of dispute raised by a Party
or any defense or objection thereto was unreasonable or made in bad faith, the arbitrator may assess, as part of the arbitration
award, all or any part of the arbitration expenses (including reasonable attorney's fees) of the other Party and the arbitration
fees against the Party raising such unreasonable matter of dispute or defense or objection thereto.

 

(iii)        In
construing this Agreement and disputes arising hereunder, the arbitrator shall apply the law of the State of California, without
regard to its conflict of laws principles.

 

(iv)        There
shall be a stenographic transcription of the arbitration proceedings, the costs thereof to be shared equally by the Parties.

 

(v)         Upon
an application to a court of competent jurisdiction with respect to an award rendered by the arbitrator, any court having jurisdiction
may enter judgment upon any award either by confirming the award, or by vacating, modifying or correcting the award. The court
shall vacate, modify or correct any award: (A) where the arbitrator's findings of fact are not supported by substantial evidence,
or (B) where the arbitrator's conclusions of law are erroneous.

 

(vi)        This
arbitration clause, and its enforcement, shall be governed by the laws of the State of California.

 

17.         Notices.
All notices, claims, certificates, demands and other communications hereunder shall be deemed to have been duly given if personally
delivered or sent by nationally-recognized overnight courier, by telecopy, or registered mail, return receipt required and postage
prepaid, addressed as follows:

 

If to Employee, to:

 

Eric Marcusson

260 King Street #727

San Francisco, CA 94107

with a copy to:

 

    	10

    	 

    

 

If to the Company, to:

 

Microlin Bio, Inc.

Attn: Joseph Hernandez

392A West 12th Street, Suite 114

New York, NY 10014

 

or to such other address as the Party to
whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice or communication
shall be deemed to have been delivered (a) in the case of personal delivery, on the date of such delivery; (b) in the case of a
nationally-recognized overnight courier, on the next business day after the notice was sent; (c) in the case of telecopy transmission,
when received; and (d) in the case of mailing, on the third business day following posting.

 

18.         Entire
Agreement. This Agreement and the other writings referred to herein or delivered pursuant hereto which form a part hereof
contain the entire agreement among the Parties with respect to the subject matter hereof, and supersede all prior and contemporaneous
arrangements or understandings (whether written or oral) with respect thereto, including but not limited to, any offer letter or
correspondence or consulting agreement. Notwithstanding the foregoing, except as otherwise required by law, the non-competition,
non-solicitation, confidentiality and inventions provisions of any agreement between Employee and the Company shall survive the
execution and delivery of this Agreement and remain in full force and effect in accordance with their terms.

 

19.         Successors
and Assigns; Assignments. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns
and Employee and Employee's heirs, personal representatives, successors and permitted assigns. This Agreement is personal in its
nature, and Employee shall not, without the written consent of the Company, assign or transfer this Agreement or any rights or
obligations hereunder.

 

20.         Governing
Law.  This Agreement, its enforcement and the performance of the Parties hereunder, and all suits and special proceedings
that may ensue from its breach, shall be construed in accordance with and under the laws of the State of California, without regard
to its conflict of laws principles. The Parties agree that if for any reason the arbitration provisions hereof are found to be
unenforceable, any action with respect to or arising out of this Agreement shall be brought and maintained in a state or federal
court of competent jurisdiction located in San Francisco, California. The Parties irrevocably consent to the personal jurisdiction
of and venue in such court.

 

21.         Waivers;
Amendments. The provisions of this Agreement may not be waived, except pursuant to a writing executed by the person against
whom enforcement of such waiver would be sought. Either Party's failure to enforce any provision or provisions of this Agreement
shall not in any way be construed as a waiver of any such provision or provisions, or prevent that Party thereafter from enforcing
each and every other provision of this Agreement. This Agreement may not be modified or amended without the written consent of
each of the Parties.

 

    	11

    	 

    

 

22.         Counterparts.
 This Agreement may be executed in any number of counterparts and by facsimile, and each such counterpart hereof shall be
deemed to be an original instrument, but all such counterparts together shall constitute but one agreement.

 

23.         Headings;
Interpretation.  Titles and headings to paragraphs in this Agreement are for the purpose of reference only and shall
in no way limit, define or otherwise affect its provisions. The provisions of this Agreement shall be interpreted in accordance
with their plain meaning. No provision of this Agreement shall be interpreted against a Party by reason of that Party or its legal
counsel having been responsible for the drafting of the provision. As used in this Agreement all pronouns and any variations thereof
refer to the masculine, feminine or neuter, singular or plural, as the context may require.

 

24.         Severable
Provisions.  The provisions of this Agreement are severable, and if any one or more provisions are determined to
be judicially unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

 

25.         Employee’s
Representations.

 

(a)          Employee
represents and warrants that Employee is not subject to any non-compete, non-solicit or confidentiality agreement or understanding
and is free to enter into this Agreement and to perform each of the terms and covenants hereof. Employee further represents and
warrants that Employee is not restricted or prohibited, contractually or otherwise, from entering into and performing this Agreement,
and that Employee's execution and performance of this Agreement is not a violation or a breach of any other agreement or understanding
between Employee and any other person or entity.

 

(b)          Employee
agrees that during the Employment Period he shall not improperly use or disclose any confidential or proprietary information or
trade secrets of any former employers or principals, partners, co-venturers, clients, customers or suppliers of former employers,
and Employee agrees that he shall not bring onto any Company premises, or download or copy to any Company computers or other equipment,
any unpublished document or any property (including intellectual property) belonging to such persons or entities without their
prior consent. Employee further agrees that he shall not violate any non-disclosure or proprietary rights agreement he might have
signed in connection with any such person or entity.

 

26.         Acknowledgment.
THE PARTIES HERETO, BY SIGNING BELOW, ATTEST THAT THEY HAVE READ AND UNDERSTOOD THIS DOCUMENT, AND ARE KNOWINGLY AND VOLUNTARILY
AGREEING TO ITS TERMS. ADDITIONALLY, EMPLOYEE REPRESENTS THAT EMPLOYEE HAS BEEN ADVISED THAT EMPLOYEE HAS THE RIGHT TO REVIEW ALL
ASPECTS OF THIS AGREEMENT WITH AN ATTORNEY OF EMPLOYEE'S CHOICE, THAT EMPLOYEE HAS HAD THE OPPORTUNITY TO CONSULT WITH AN ATTORNEY
OF EMPLOYEE'S CHOICE, AND THAT EMPLOYEE HAS CAREFULLY READ AND FULLY UNDERSTANDS ALL THE PROVISIONS OF THIS AGREEMENT.

 

[signature page
follows]

 

    	12

    	 

    

 

IN WITNESS WHEREOF,
the Parties have duly executed this Agreement on the date first above written.

 

	 	 	Microlin Bio, Inc. 
	 	 	 
	 	By:	/s/ Joseph Hernandez
	 	 	
        Joseph Hernandez

        Chief Executive Officer

	 	 	Date: March 7, 2014
	 	 	 
	 	 	/s/ Eric G. Marcusson, Ph.D.
	 	 	
        Eric G. Marcusson, Ph.D.

        Date: March 7, 2014

 

    	13

    	 

    

 

Exhibit A

 

MICROLIN BIO INC.

NONQUALIFIED STOCK OPTION AGREEMENT

 

Notice of Stock Option
Grant

 

MicroLin Bio Inc.,
a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the Microlin
Bio Inc. Equity Incentive Plan (the “Plan”) and this Nonqualified Stock Option Agreement (this “Agreement”),
an option (the “Stock Option”) to purchase the number of Shares at the exercise price per share (“Exercise Price”)
as follows:

 

	Name of Grantee:	Eric G. Marcusson
	 	 
	Number of Shares: 	10,000
	 	 
	Exercise Price:	$12.65 per Share
	 	 
	Date of Grant:	December 31, 2013
	 	 
	Vesting Dates: 	November 22, 2014 and the first day of each month for thirty-six months thereafter, commencing December 1, 2014

 

Terms of Agreement

 

1.          Grant
of Stock Option. Subject to and upon the terms, conditions and restrictions set forth in this Agreement and in the Plan, the
Company hereby grants to the Grantee as of the Date of Grant this Stock Option to purchase the number of Shares at the Exercise
Price as set forth above. This Stock Option is intended to be a nonqualified stock option and shall not be treated as an “incentive
stock option” within the meaning of that term under Section 422 of the Code.

 

2.          Vesting
of Stock Option.

 

     (a)          Unless
and until terminated as hereinafter provided, the Stock Option shall vest and become exercisable as follows:

 

    (i)         With respect
to twenty-five percent (25%) of the Shares subject to the Stock Option, on November 22, 2014, provided that the Grantee shall have
remained in the continuous employment or other service of the Company or a Subsidiary through such Vesting Date; and

 

    (ii)         With
respect to seventy-five percent (75%) of the Shares subject to the Stock Option, ratably, on the first day of each month for thirty-six
months, commencing December 1, 2014, provided that the Grantee shall have remained in the continuous employment or other service
of the Company or a Subsidiary through each such Vesting Date.

 

    	1

    	 

    

 

     (b)          Notwithstanding
the provisions of Section 2(a), the Stock Option will become immediately vested and exercisable in full if, prior to the applicable
Vesting Date: (i) the Grantee’s employment or service with the Company and its Subsidiaries terminates by reason of the Grantee’s
death or “Disability” (defined as permanent and total disability within the meaning of Section 22(e)(3) of the Code);
or (ii) the Grantee’s employment or service is terminated within two years after a Change in Control: (A) by the Company
and its Subsidiaries without Cause and not as a result of Disability; or (B) by the Grantee for Good Reason (defined as in Section
2(c) of this Agreement).

 

     (c)          For
purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following without the Grantee’s
consent: (i) a material reduction of the Grantee’s annual base salary; (ii) a material reduction in the Grantee’s title,
authority, responsibilities or reporting relationship as in effect immediately prior to the Change in Control; or (iii) the Company’s
requirement that in order to perform his obligations to the Company, the Grantee must relocate his residence to a location more
than fifty (50) miles from the Grantee’s principal office location immediately prior to a Change in Control. A termination
of the Grantee’s employment or service by the Grantee shall not be deemed to be for Good Reason unless (x) the Grantee gives
notice to the Company of the existence of the event or condition constituting Good Reason within 60 calendar days after such event
or condition initially occurs or exists, and (y) the Company fails to cure such event or condition within 30 calendar days after
receiving such notice.

 

     (d)          For
purposes of this Agreement, the continuous employment or service of the Grantee with the Company and its Subsidiaries shall not
be deemed to have been interrupted, and the Grantee shall not be deemed to have ceased to be an employee of, or service provider
to, the Company and its Subsidiaries, by reason of the transfer of his employment or service among the Company and its Subsidiaries
or a leave of absence approved by the Board.

 

3.          Forfeiture
of Stock Option.

 

     (a)          To
the extent that the Stock Option has not yet vested pursuant to Section 2 above, it shall be forfeited automatically without further
action or notice if the Grantee ceases to be employed by, or to provide services to, the Company and its Subsidiaries prior to
the applicable Vesting Date other than as provided in Section 2(b).

 

     (b)          The
provisions of Section 17 of the Plan regarding forfeiture of Awards shall apply to the Stock Option and any Shares delivered hereunder.
This Section 3(b) shall survive and continue in full force in accordance with its terms notwithstanding any termination of the
Grantee’s employment or service or the exercise of the Stock Option as provided herein.

 

4.          Exercise
of Stock Option.

 

     (a)          To
the extent that the Stock Option has become vested and exercisable in accordance with this Agreement, it may be exercised in whole
or in part from time to time by written notice to the Company stating the number of whole Shares for which the Stock Option is
being exercised, the intended manner of payment, and such other provisions as may be required by the Company. The Stock Option
may be exercised, during the lifetime of the Grantee, only by the Grantee, or in the event of his legal incapacity, by his guardian
or legal representative acting on behalf of the Grantee in a fiduciary capacity under state law and/or court supervision. If the
Grantee dies before the expiration of the Stock Option, all or part of this Stock Option may be exercised (prior to expiration)
by the personal representative of the Grantee or by any person who has acquired this Stock Option directly from the Grantee by
will, bequest or inheritance, but only to the extent that the Stock Option was vested and exercisable upon the Grantee’s
death.

 

    	2

    	 

    

 

     (b)          The
Exercise Price is payable in cash or by certified or cashier’s check or other cash equivalent acceptable to the Board payable
to the order of the Company.

 

5.          Term
of Stock Option. Subject to Section 3(b) hereof, the Stock Option will terminate on the earliest of the following dates (the
“Expiration Date”):

 

     (a)          Twelve
(12) months after the termination of the Grantee’s employment or service as a result of death or Disability;

 

     (b)          Immediately
upon termination of the Grantee’s employment or service by the Company for Cause;

 

     (c)          Ninety
(90) days after the termination of the Grantee’s employment or service for any other reason; or

 

     (d)          Midnight
on the day immediately preceding the tenth anniversary of the Date of Grant.

 

6.          Delivery
of Shares. Subject to the terms and conditions of this Agreement and the Plan, Shares shall be issuable to the Grantee as soon
as administratively practicable following the date the Grantee (a) exercises the Stock Option in accordance with Section 4 hereof,
(b) makes full payment to the Company of the Exercise Price and (c) makes arrangements satisfactory to the Company (or any Subsidiary,
if applicable) for the payment of any required withholding taxes related to the exercise of the Stock Option. The Grantee shall
not possess any incidents of ownership (including, without limitation, dividend or voting rights) in the Shares until such Shares
have been issued to the Grantee in accordance with this Section 6.

 

7.          Transferability.
The Stock Option may not be sold, exchanged, assigned, transferred, pledged, encumbered or otherwise disposed of by the Grantee;
provided that the Grantee’s rights with respect to such Stock Option may be transferred by will or pursuant to the laws of
descent and distribution. Any purported transfer or encumbrance in violation of the provisions of this Section 7 shall be void,
and the other party to any such purported transaction shall not obtain any rights to or interest in such Stock Option.

 

8.          Restrictions
on Resale. Unless and until registered under the Securities Act of 1933, as amended (the “Securities Act”), any
Shares purchased pursuant to the Stock Option will be illiquid and will be deemed to be “restricted securities” for
purposes of the Securities Act. Accordingly, any such Shares may be sold only in compliance with the registration requirements
of the Securities Act or an exemption therefrom and may need to be held indefinitely. Unless and until the Shares have been registered
under the Securities Act, each certificate evidencing any of the Shares shall bear a restrictive legend specified by the Company.

 

    	3

    	 

    

 

9.          Company’s
Right to Repurchase Shares.

 

     (a)          The
Company shall have the right (the “Repurchase Right”) to repurchase all, but not less than all, of the Shares purchased
by the Grantee pursuant to the Stock Option, upon written notice to the Grantee within ninety (90) days after the termination of
the Grantee’s employment or service with the Company and its Subsidiaries, voluntarily or involuntarily, for any reason whatsoever
other than by the Company for Cause, including as a result of death or Disability. The Repurchase Right shall be exercised by the
Company by giving the holder of the Shares written notice of its intention to exercise the Repurchase Right, and, together with
such notice, tendering to the holder an amount equal to the Fair Market Value of the Shares. Upon timely exercise of the Repurchase
Right in the manner provided in this Section 9(a), the holder of the Shares shall deliver to the Company any stock certificate
or certificates representing the Shares being repurchased, duly endorsed and free and clear of any and all liens, charges and encumbrances.
If Shares are not repurchased under the Repurchase Right, the Grantee and his successor in interest, if any, will continue to hold
the Shares subject to all of the provisions of this Agreement and the Plan.

 

     (b)          In
the event that the Company or a Subsidiary terminates the Grantee’s employment or service for Cause, the Company’s
rights with respect to any Shares purchased by the Grantee pursuant to the Stock Option shall be governed by Section 3(b) of this
Agreement and Section 17 of the Plan.

 

10.         No
Right to Continued Employment or Service. Nothing contained in this Agreement shall confer upon the Grantee any right with
respect to continuance of employment by or service with the Company and its Subsidiaries, nor limit or affect in any manner the
right of the Company and its Subsidiaries to terminate the employment or service of the Grantee or adjust the Grantee’s compensation.

 

11.         Relation
to Other Benefits. Any economic or other benefit to the Grantee under this Agreement or the Plan shall not be taken into account
in determining any benefits to which the Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation
plan or arrangement maintained by the Company or a Subsidiary.

 

12.         Taxes
and Withholding. The Grantee shall pay to the Company, or make arrangements satisfactory to the Company for payment of, any
federal, state, local or other taxes that the Company or any Subsidiary is required to withhold in connection with the delivery
of Shares under this Agreement. The obligation of the Company to deliver Shares under this Agreement shall be conditioned on such
payment or arrangements, and the Company and its Subsidiaries shall, to the extent permitted by Applicable Law, have the right
to deduct any such taxes from any payment otherwise due to the Grantee.

 

13.         Compliance
with Applicable Law. The Company shall make reasonable efforts to comply with Applicable Law (including applicable federal
and state securities laws) with respect to the Stock Option; provided that, notwithstanding any other provision of this Agreement,
and only to the extent permitted under Section 409A of the Code, the Company shall not be obligated to deliver any Shares pursuant
to this Agreement if the delivery thereof would result in a violation of Applicable Law.

 

    	4

    	 

    

 

14.         Adjustments.
The Exercise Price and the number and kind of shares of stock covered by this Agreement shall be subject to adjustment as provided
in Section 13 of the Plan.

 

15.         Amendments.
Subject to the terms of the Plan, the Board may modify this Agreement upon written notice to the Grantee. Any amendment to the
Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto. Notwithstanding
the foregoing, no amendment of the Plan or this Agreement shall adversely affect the rights of the Grantee under this Agreement
in a material way without the Grantee’s consent, except as otherwise may be provided in the Plan.

 

16.         Severability.
In the event that one or more of the provisions of this Agreement shall be invalidated for any reason by a court of competent jurisdiction,
any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof
shall continue to be valid and fully enforceable.

 

17.         Relation
to Plan. This Agreement is subject to the terms and conditions of the Plan, including the forfeiture provisions of Section
17 of the Plan. This Agreement and the Plan contain the entire agreement and understanding of the parties with respect to the subject
matter contained in this Agreement, and supersede all prior written or oral communications, representations and negotiations in
respect thereto. In the event of any inconsistency between the provisions of this Agreement and the Plan, the Plan shall govern.
Capitalized terms used herein without definition shall have the meanings assigned to them in the Plan. The Board shall have the
right to determine any questions which arise in connection with the grant of the Stock Option.

 

18.         Successors
and Assigns. Without limiting Section 7 hereof, the provisions of this Agreement shall inure to the benefit of, and be binding
upon, the successors, administrators, heirs, legal representatives and assigns of the Grantee, and the successors and assigns of
the Company.

 

19.         Governing
Law. The interpretation, performance, and enforcement of this Agreement shall be governed by the laws of the State of Delaware,
excluding any conflicts or choice of law rule or principle that might otherwise refer interpretation or enforcement of the Agreement
to the substantive law of another jurisdiction.

 

20.         Use
of Grantee’s Information. Information about the Grantee and the Grantee’s participation in the Plan may be collected,
recorded and held, used and disclosed for any purpose related to the administration of the Plan. The Grantee understands that such
processing of this information may need to be carried out by the Company and its Subsidiaries and by third party administrators
whether such persons are located within the Grantee’s country or elsewhere, including the United States of America. The Grantee
consents to the processing of information relating to the Grantee and the Grantee’s participation in the Plan in any one
or more of the ways referred to above.

 

    	5

    	 

    

 

21.         Relationship
to Consulting Agreement. Grantee and the Company acknowledge and agree that (a) the Option granted hereby is granted in
full satisfaction of the Company’s obligations pursuant to Section 3(a) of that certain Consulting Agreement, dated
November 22, 2013, between Grantee and the Company (the “Consulting Agreement”); (b) this Agreement, together
with the Plan, contains the entire agreement and understanding of the parties with respect to the subject matter contained in this
Agreement, and supersedes all prior written and oral communications, representations and negotiations in respect thereto, including,
without limitation, Section 3(a) of the Consulting Agreement; and (c) except as set forth herein, Grantee has no right
to or interest in any equity securities, including options to acquire any equity securities, of the Company.

 

[SIGNATURE PAGE FOLLOWS]

 

    	6

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Agreement to be executed on its behalf by its duly authorized officer and the Grantee has also executed
this Agreement, as of the Date of Grant.

 

	 	MICROLIN BIO INC.	 
	 	 	 
	 	By:	/s/ Joseph Hernandez	 
	 	 	Joseph Hernandez	 
	 	 	Executive Chairman	 

 

The undersigned Grantee
hereby acknowledges receipt of a copy of the Plan. The Grantee represents that he is familiar with the terms and provisions of
the Plan, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and hereby accepts the Stock
Option on the terms and conditions set forth herein and in the Plan.

 

	 	GRANTEE	 
	 	 	 
	 	/s/ Eric G. Marcusson	 
	 	Eric G. Marcusson	 
	 	 	 

 

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]